In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2

Journal of Immunology

Volumn 134, Issue 1, 1985, Pages 157-166

  Lotze, M T ^a   Frana, L W ^a   Sharrow, S O ^a   Robb, R J ^b   Rosenberg, S A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; PHORBOL 13 ACETATE 12 MYRISTATE; PHYTOHEMAGGLUTININ;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BIOAVAILABILITY; CANCER; CLINICAL ARTICLE; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; MACROPHAGE; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; T LYMPHOCYTE; THERAPY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; DRUG EVALUATION; FEMALE; HALF-LIFE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; LUNG NEOPLASMS; LYMPHOCYTES; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS; SARCOMA; SARCOMA, KAPOSI; SKIN NEOPLASMS;

EID: 0021948339     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)